Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TYR | P14679 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.37 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21089 | 0.82 | MIF (0.44) | TSHR | |
| SCHEMBL22471901 | 0.80 | MIF (0.43) | TSHR | |
| Water SCHEMBL29040332 | 0.80 | MIF (0.43) | TSHR | |
| Water SCHEMBL14972874 | 0.80 | MIF (0.43) | TSHR | |
| SCHEMBL460071 | 0.80 | POLB (0.34) | BCHEACHE | |
| SCHEMBL8816811 | 0.80 | GABRA1 (0.37) | — | |
| SCHEMBL3855689 | 0.80 | MIF (0.57) | TSHRCA2TP53CA1BCHE | |
| SCHEMBL1648872 | 0.80 | MIF (0.49) | BCHEACHE | |
| SCHEMBL436823 | 0.79 | IDO1 (0.42) | TSHRCA2TP53CA1ACHE | |
| SCHEMBL28911605 | 0.78 | KCNH2 (0.49) | TSHRCA2TP53CA1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116396192-A | Diurea anti-sagging agent and synthesis method thereof | 天津大学 | 2023-07-07 | — | — | CN | claimed |
| CN-116063588-A | Sagging-resistant resin and preparation method and application thereof | 天津大学 | 2023-05-05 | — | — | CN | claimed |
| CN-116396192-A | Diurea anti-sagging agent and synthesis method thereof | 天津大学 | 2023-07-07 | — | — | CN | disclosed |
| CN-116063588-A | Sagging-resistant resin and preparation method and application thereof | 天津大学 | 2023-05-05 | — | — | CN | disclosed |
| CN-116063588-A | Sagging-resistant resin and preparation method and application thereof | 天津大学 | 2023-05-05 | — | — | CN | disclosed |
| CN-111057002-B | Synthetic method of 2-aminoquinolone compound | 西安交通大学 | 2021-08-13 | — | — | CN | disclosed |
| CN-111057002-A | Synthetic method of 2-aminoquinolone compound | 西安交通大学 | 2020-04-24 | — | — | CN | disclosed |
| US-20160068559-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | Epizyme, Inc. | 2016-03-10 | — | — | US | disclosed |
| US-9029343-B2 | Modulators of histone methyltransferase, and methods of use thereof | Epizyme, Inc. (US) | 2015-05-12 | — | — | US | disclosed |
| US-8642657-B2 | 4-(methyl sulfonyl amino) phenyl analogues as vanilloid antagonist showing excellent analgesic activity and the pharmaceutical compositions comprising the same | GRUENENTHAL GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| US-8642657-B2 | 4-(methyl sulfonyl amino) phenyl analogues as vanilloid antagonist showing excellent analgesic activity and the pharmaceutical compositions comprising the same | GRUENENTHAL GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| US-20040157849-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2004-08-12 | — | — | US | disclosed |
| US-20040044003-A1 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. | 2004-03-04 | — | — | US | disclosed |
| WO-2003070247-A1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2003-08-28 | — | — | WO | disclosed |
| US-20030158198-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2003-08-21 | — | — | US | disclosed |
| US-20030153596-A1 | Novel thiourea derivatives and the pharmaceutical compositions containing the same | PACIFIC CORPORATION (KR) | 2003-08-14 | — | — | US | disclosed |
| WO-2003066595-A2 | 2 - PIPERAZINE - PYRIDINES USEFUL FOR TREATING PAIN | EURO-CELTIQUE S.A. (LU) | 2003-08-14 | — | — | WO | disclosed |
| EP-1303483-A1 | NOVEL THIOUREA DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | PACIFIC CORPORATION (KR) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002016318-A1 | NOVEL THIOUREA DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | PACIFIC CORPORATION (KR) | 2002-02-28 | — | — | WO | disclosed |
| WO-1997011052-A1 | UREA DERIVATIVES AND THEIR USE AS ANALGESICS AND ANTIINFLAMMATORY AGENTS | NOVARTIS AG (CH) | 1997-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153596-A1 | Novel thiourea derivatives and the pharmaceutical compositions containing the same | TAS2R40, TAS1R2, TAS2R45 | TSHR 74/4885CA2 1239/4885TP53 3496/4885 |
| US-20030158198-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, VIPR1, TMEM109 | TSHR 3724/4885CA2 1657/4885TP53 3579/4885 |
| US-20040157849-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, VIPR1, TMEM109 | TSHR 3722/4885CA2 1619/4885TP53 3598/4885 |
| US-20160068559-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | EHMT1, EHMT2, HNMT | TSHR 3496/4885CA2 3631/4885TP53 1478/4885 |
| US-20040044003-A1 | Therapeutic agents useful for treating pain | GRIK5, HBS1L, GABRR1 | TSHR 2025/4885CA2 3927/4885TP53 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.